Tumor Biomarkers in Melanoma

Ohsie S.J. , Sarantopoulos G.P. , Cochran A.J. . Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008; 35(5): 433–444.

Niezabitowski A. , Czajecki K. , Ryś J. ,. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohisto-chemical study. J Surg Oncol. 1999; 70(3): 150–160.

Berger A.J. , Davis D.W. , Tellez C. . Automated quantitative analysis of activator protein-2alpha subcellular expression in mela-noma tissue microarrays correlates with survival prediction. Cancer Res. 2005; 65(23): 11185–11192.

Alonso S.R. , Ortiz P. , Pollán M. , Pérez-Gómez B. . Progression in cutaneous malignant mela-noma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol. 2004; 164(1): 193–203.

Janku F. , Novotny J. , Julis I. . KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res. 2005; 15(4): 251–256.

Cruz J. , Reis-Filho J.S. , Silva P. . Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology. 2003; 65(1): 72–82.

Kraehn G.M. , Utikal J. , Udart M. . Extra c-myc oncogene copies in high risk cutaneous malignant mela-noma and mela-noma metastases. Br J Cancer. 2001; 84(1): 72–79.

Massoumi R. , Kuphal S. , Hellerbrand C. . Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009; 206(1): 221–232. Epub 2009 Jan 5.

Udart M. , Utikal J. , Krähn G.M. . Chromosome 7 aneusomy: a marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001; 3(3): 245–254.

Jovanovic B. , Kröckel D. , Linden D. . Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol. 2008; 128(11): 2696–2704. Epub 2008 May 29.

Reschke M. , Mihic-Probst D. , van der Horst E.H. . HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res. 2008; 14(16): 5188–5197.

Polsky D. , Melzer K. , Hazan C. . HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst. 2002; 94(23): 1803–1806.

Wang Y. , Dai D.L. , Martinka M. . Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin Cancer Res. 2007; 13(14): 4111–4116.

Ugurel S. , Houben R. , Schrama D. . Microphthalmia-associated transcription factor gene amplification in metastatic mela-noma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res. 2007; 13(21): 6344–6350.

Mihic-Probst D. , Mnich C.D. , Oberholzer P.A. . p16 expression in primary malignant mela-noma is associated with prognosis and lymph node status. Int J Cancer. 2006; 118(9): 2262–2268.

Dai D.L. , Martinka M. , Li G. . Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol. 2005; 23(7): 1473–1482.

Roesch A. , Becker B. , Meyer S. . Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod Pathol. 2005; 18(4): 565–572.

Mikhail M. , Velazquez E. , Shapiro R. . PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res. 2005; 11(14): 5153–5157.

Flørenes V.A. , Maelandsmo G.M. , Faye R. . Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001; 195(5): 530–536.

Flørenes V.A. , Faye R.S. , Maelandsmo G.M. . Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000; 6(9): 3614–3620.

Winnepenninckx V. , Lazar V. , Michiels S. . Gene expression profiling of primary cutaneous mela-noma and clinical outcome. J Natl Cancer Inst. 2006; 98(7): 472–482.

Gimotty P.A. , Van Belle P. , Elder D.E. . Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005; 23(31): 8048–8056.

Ostmeier H. , Fuchs B. , Otto F. . Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001; 145(2): 203–209.

Fujimoto A. , Takeuchi H. , Taback B. . Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004; 64(6): 2245–2250.

Fecker L.F. , Geilen C.C. , Tchernev G. . Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006; 126(6): 1366–1371.

Tas F. , Duranyildiz D. , Argon A. . Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004; 14(6): 543–546.

Dadras S.S. , Paul T. , Bertoncini J. . Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous mela-noma metastasis and survival. Am J Pathol. 2003; 162(6): 1951–1960.

Wu H. , Barusevicius A. , Babb J. . Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol. 2005; 32(2): 125–130.

Bachmann I.M. , Straume O. , Puntervoll H.E. . Importance of Pcadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005; 11 (24 pt 1): 8606–8614.

Thies A. , Moll I. , Berger J. . CEACAM1 expression in cutaneous malignant mela-noma predicts the development of metastatic disease. J Clin Oncol. 2002; 20(10): 2530–2536.

Nishizawa A. , Nakanishi Y. , Yoshimura K. . Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer. 2005; 103(8): 1693–1700.

Andersen K. , Nesland J.M. , Holm R. . Expression of S100A4 com-bined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol. 2004; 17(8): 990–997.

Saalbach A. , Wetzel A. , Haustein U.F. . Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating mela-noma cell adhesion to activated endothelium. Oncogene. 2005; 24(29): 4710–4720.

Redondo P. , Lloret P. , Idoate M. . Expression and serum levels of MMP-2 and MMP-9 during human mela-noma progression. Clin Exp Dermatol. 2005; 30(5): 541–545.

Massi D. , Franchi A. , Borgognoni L. . Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999; 30(3): 339–344.

Luongo V. , Pirozzi G. , Caracò C. ,. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens. 2004; 64(1): 84–87.

Swart G.W. , Lunter P.C. , Kilsdonk J.W. . Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of mela-noma cell clustering and cell migration? Cancer Metastasis Rev. 2005; 24(2): 223–236.

Scala S. , Ottaiano A. , Ascierto P.A. . Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005; 11(5): 1835–1841.

Duncan L.M. , Deeds J. , Hunter J. . Down-regulation of the novel gene melastatin correlates with potential for mela-noma metastasis. Cancer Res. 1998; 58(7): 1515–1520.

Weinlich G. , Eisendle K. , Hassler E. . Metallothionein: overexpression as a highly significant prognostic factor in melanoma. A prospective study on 1270 patients. Br J Cancer. 2006; 94: 835–841.

Rangel J. , Nosrati M. , Torabian S. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008; 112(1): 144–150.

Carvalho L. , Lipay M. , Belfort F. . Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg. 2006; 59(9): 961–968. Epub 2006 Apr 3.

Curtin J.A. , Fridlyand J. , Kageshita T. . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20): 2135–2147.

Curtin J.A. , Busam K. , Pinkel D. . Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26): 4340–4346. Epub 2006 Aug 14.

Viros A. , Fridlyand J. , Bauer J. . Improving mela-noma classification by integrating genetic and morphologic features. PLoS Med. 2008; 5(6): e120.

Ugurel S. , Schadendorf D. , Pföhler C. . In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006; 12(18): 5454–5463.

Guo H.B. , Stoffel-Wagner B. , Bierwirth T. . Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995; 31A(11): 1898–1902.

Schultz E.S. , Diepgen T.L. , Von Den Driesch P. . Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Der-matol. 1998; 138(3): 426–430.

Hauschild A. , Engel G. , Brenner W. . Predictive value of serum S100B for monitoring patients with metastatic mela-noma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999; 140(6): 1065–1071.

Krähn G. , Kaskel P. , Sander S. . S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred mela-noma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001; 21 (2B): 1311–1316.

Garbe C. , Leiter U. , Ellwanger U. . Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk mela-noma patients. Cancer. 2003; 97(7): 1737–1745.

Bogdahn U. , Apfel R. , Hahn M. . Autocrine tumor cell growthinhibiting activities from human malignant melanoma. Cancer Res. 1989; 49(19): 5358–5363.

Blesch A. , Bosserhoff A.K. , Apfel R. . Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994; 54(21): 5695–5701.

Stahlecker J. , Gauger A. , Bosserhoff A. . MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2000; 20 (6D): 5041–5044.

Agrup P. , Carstam R. , Wittbjer A. . Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol. 1989; 69(2): 120–124.

Wimmer I. , Meyer J.C. , Seifert B. . Prognostic value of serum 5-Scysteinyldopa for monitoring human metastatic mela-noma during immunochemotherapy. Cancer Res. 1997; 57(22): 5073–5076.

Stoitchkov K. , Letellier S. , Garnier J.P. . Evaluation of the serum L-dopa/L-tyrosine ratio as a mela-noma marker. Melanoma Res. 2003; 13(6): 587–593.

Ugurel S. , Rappl G. , Tilgen W. . Increased serum concentration of angiogenic factors in malignant mela-noma patients correlates with tumor progression and survival. J Clin Oncol. 2001; 19(2): 577–583.

Hirai S. , Kageshita T. , Kimura T. . Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of mela-noma progression. Melanoma Res. 1997; 7(1): 58–62.

Vuoristo M.S. , Laine S. , Huhtala H. . Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer. 2001; 37(13): 1629–1634.

Franzke A. , Probst-Kepper M. , Buer J. . Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehy-drogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer. 1998; 78(1): 40–45.

Nikkola J. , Vihinen P. , Vuoristo M.S. . High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005; 11(14): 5158–5166.

Yoshino Y. , Kageshita T. , Nakajima M. . Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol. 2008; 35(4): 206–214.

Mouawad R. , Benhammouda A. , Rixe O. . Endogenous inter-leukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 1996; 2(8): 1405–1409.

Dummer W. , Becker J.C. , Schwaaf A. . Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995; 5(1): 67–68.

Nemunaitis J. , Fong T. , Shabe P. . Comparison of serum inter-leukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001; 19(3): 239–247.

Boyano M.D. , Garcia-Vázquez M.D. , López-Michelena T. . Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer. 2000; 83(7): 847–852.

Rebmann V. , Ugurel S. , Tilgen W. . Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage mela-noma patients. Int J Cancer. 2002; 100(5): 580–585.

Westhoff U. , Fox C. , Otto F.J. . Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res. 1998; 18 (5B): 3789–3792.

Sirott M.N. , Bajorin D.F. , Wong G.Y. . Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993; 72(10): 3091–3098.

Deichmann M. , Kahle B. , Moser K. . Diagnosing mela-noma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer. 2004; 91(4): 699–702.

Ugurel S. , Bell N. , Sucker A. . Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005; 117(5): 825–830.

Ugurel S. , Rappl G. , Tilgen W. . Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in mela-noma patients. Clin Cancer Res. 2001; 7(5): 1282–1286.

Schmidt H. , Johansen J.S. , Sjoegren P. . Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006; 24(5): 798–804. Epub 2006 Jan 3.

Schmidt H. , Johansen J.S. , Gehl J. . Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006; 106(5): 1130–1139.

Vergilis I.J. , Szarek M. , Ferrone S. . Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol. 2005; 125(3): 526–531.

Hahn S. , Ugurel S. , Hanschmann K.M. . Serological response to human endogenous retrovirus K in mela-noma patients correlates with survival probability. AIDS Res Hum Retroviruses. 2008; 24(5): 717–723.

Persson L. , Hårdemark H.G. , Gustafsson J. . S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987; 18(5): 911–918.

Deichmann M. , Benner A. , Bock M. . S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999; 17(6): 1891–1896.

Jury C.S. , McAllister E.J. , MacKie R.M. . Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol. 2000; 143(2): 269–274.

Acland K. , Evans A.V. , Abraha H. . Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol. 2002; 146(5): 832–835.

Balch C.M. , Buzaid A.C. , Soong S.J. . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19(16): 3635–3648.

Mian S. , Ugurel S. , Parkinson E. . Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in mela-noma patients. J Clin Oncol. 2005; 23: 5088–5093.

Findeisen P. , Zapatka M. , Peccerella T. . Serum amyloid A as a prognostic marker in mela-noma identified by proteomic profiling. J Clin Oncol. 2009 Mar 23. Epub ahead of print.